Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q1 2020 · 10-Q
Revenue$9.60M$9.60M−10.1% vs Q1 2019 Net Income-$1.78M-$1.78MN/M vs Q1 2019 EPS Diluted-$0.60-$0.60N/M vs Q1 2019 Gross Profit$1,881,566−12.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flow-$2,293,105N/M Margins · derivedGross margin19.6%−0.4 pt vs Q1 2019
Operating margin-16.7%−4.5 pt vs Q1 2019
Net margin-18.6%−1.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 15, 2020 · 45 d after period end